Overview

Tipranavir Expanded Access Program (EAP) in PI-experienced Patients With HIV-1 Infection

Status:
Approved for marketing
Trial end date:
1969-12-31
Target enrollment:
0
Participant gender:
Summary
This study was designed to provide early access to and evaluate the safety of TPV/r in PI-experienced patients with HIV-1 infection.
Details
Lead Sponsor:
Boehringer Ingelheim
Treatments:
Ritonavir
Tipranavir